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The production of bioactive compounds in heterologous hosts has become a valuable tool for the investiga-
tion of biosynthetic pathways and their rational engineering. In this issue of Chemistry & Biology, Zhang et al.
(2010) report the manipulation of E. coli for the production of erythromycin A.Many bioactive compounds, including
clinically important antibiotics such as
erythromycin, are synthesized by micro-
organisms that often are only poorly
accessible by molecular genetic tech-
niques. Thus, genetic engineering of
these biosynthetic pathways requires
substantial efforts as basic protocols for
gene transfer, DNA isolation, and muta-
genesis have to be individually developed
for each producing strain. Therefore, the
expression of complete biosynthetic
pathways in heterologous hosts is a prom-
ising way to engineer and improve such
compounds. Heterologous expression of
small gene clusters encoding biosyn-
thesis of aromatic polyketides has already
resulted in good yields (see Lopez et al.,
2010) and allowed the manipulation of
the pathways by standard methodology.
Using this approach, derivatives of the
natural compounds could be generated
in a much easier way, when compared
with engineering the original producing
strains. Nevertheless, these studies
mostly used closely related expression
hosts.
However, basic knowledge of growth,
cultivation properties, metabolism and
physiology, and the availability of molec-
ular tools are scarce in these heterologous
production hosts in comparison with the
model organism of choice for molecular
biology, Escherichia coli. Therefore, manyefforts have been undertaken to make
E. coli available as a host for the heterolo-
gous production of secondarymetabolites
(for review, see Gao et al., 2010); thus far,
only few success stories have been re-
ported. These include the production
of amorpha-4,11-diene, a precursor of
artemisinin (Martin et al., 2003), 2,6-
dimethyl-3,5,7-trihydroxy-7-(30-amino-50-
hydroxyphenyl)-2,4-heptadienoic acid, a
precursor of rifamycin (Watanabe et al.,
2003), epothilone B and C (Mutka et al.,
2006) or the production of several fungal
and plant polyketides (for review, see
Gao et al., 2010).
In 2001, the biosynthesis of 6-deoxyer-
ythronolide B (6-dEB), the macrocyclic
core of the antibacterial macrolide eryth-
romycin A, in a rationally engineered
E. coli strain was described (Pfeifer et al.,
2001). The E. coli strain BAP1 was con-
structed via the expression of the Bacillus
subtilis phosphopantetheinyl transferase
Sfp, and BAP1 was now able to attach
thephosphopantetheinyl prosthetic group
essential for the activity of the erythro-
mycin polyketide synthase. In addition,
its metabolism was optimized to provide
the 6-dEB building blocks in sufficient
amounts by deleting genes involved in
propionate catabolism and by introducing
genes for propionyl-CoA and (2S)-methyl-
malonyl-CoA biosynthesis. Initially, yields
of 20 mg 3 l1 of the biologically inactiveerythromycin precursor 6-dEB were ob-
tained in the BAP1 host, which could be
increased by process optimization up to
1.1 g 3 l1 (Lau et al., 2004).
In the following years, further steps
were described to reconstitute the
complete erythromycin biosynthetic
pathway in E. coli. The combination of
two tailoring genes and 14 genes involved
in deoxysugar biosynthesis and the
attachment of the macrolide megalomicin
biosynthetic gene cluster in the E. coli
strain producing 6-dEB resulted in the
heterologous production of erythromycin
D and erythromycin C at low titers (Peiru´
et al., 2005). However, with this approach,
the heterologous production of the
biosynthetic end product erythromycin A
had not been achieved.
In this issue of Chemistry & Biology,
Zhang et al. (2010) report the reconstruc-
tion of the erythromycin A biosynthetic
pathway of Saccharopolyspora erythraea
in E. coli BAP1. In addition to the erythro-
mycin PKS genes, the authors assembled
17 genes responsible for deoxysugar
biosynthesis, macrolide tailoring, and
resistance of S. erythraea into two
operons, placing eryBI-BVII and ermE
and eryCI-CVI, eryF, eryG, eryK under
the control of T7 promoters. In a first
approach, a two host strategy was
applied: the precursor 6-dEB was
produced in the previously described
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Previewsstrain expressing the three erythromycin
polyketide synthases DEBS1-3 (Pfeifer
etal., 2001), extracted,and fed toasecond
E. coli strain expressing the eryBI-BVII,
ermE and eryCI-CVI, eryF, eryG, eryK
operons and the chaperon system
GroEL/GroES. Clear signals for erythro-
mycin B and D were detected but none
for erythromycin A. This indicated that
the activity of the P450 hydroxylase gene
eryK, the last gene in an operon of nine
genes, was not expressed, probably due
to its position in the operon. After reintro-
ducing a second copy of the eryK gene
under the control of an extra T7 promoter,
erythromycin C and also the bioactive
erythromycin A were produced in yields
of2mg3 l1and10mg3 l1, respectively.
When the authors combined expression
constructs containing all 20 S. erythraea
erythromycin biosynthesis genes in
a single strain, erythromycin A was
detected in titers of 0.6mg3 l1. Although
this yield is still far away from titers
obtained by S. erythraea industrial pro-
ducers, which reach up to 7.5 g 3 l1, it
demonstrates that heterologous expres-
sion of complex type I polyketide biosyn-
thesis pathways is feasible in E. coli. It isvery likely that these titers now can be
optimized using standard strain improve-
ment technologies established for E. coli.
The authors also succeeded in gener-
ating glycosylated erythromycin analogs
in the heterologous E. coli host by replac-
ing the native erythromycin polyketide
synthase genes with engineered variants
(Liu et al., 1997; Pfeifer et al., 2001) in
titers between 0.05-0.49 mg 3 l1. Such
further reduction in productivity is
frequently observed when engineered
biosynthetic genes are expressed in the
original producers.
Although it is rather unlikely that E. coli
will replace industrial production strains
for the production of wild-type com-
pounds, it will be undoubtedly an inter-
esting alternative for combinatorial
biosynthesis and pathway engineering
approaches, as these can be carried out
much easier in the heterologous E. coli
system than in the native hosts or closely
related organisms.REFERENCES
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